Industry Insights Seminar Series: Targeting the Aryl Hydrocarbon Receptor (AHR) as a novel immunotherapy for the treatment of cancer

2nd February 2021 @ 12:00 pm - 1:30 pm
Loading Events

« All Events

  • This event has passed.

This session of the Industry Insights Seminar Series will be presented by Dr Ilona Gutcher – Group Leader Oncology, Bayer AG.

To register, please use the ‘select a date’ button
2 FEBRUARY 2021: Targeting the Aryl Hydrocarbon Receptor (AHR) as a novel immunotherapy for the treatment of cancer

Presenter: Ilona Gutcher – Group Leader Oncology, Bayer AG.

Abstract: Current approved cancer immunotherapy treatments focus on stimulating anti-tumor T cell responses with antibodies against PD1/PD-L1 and CTLA4. However, tumor cells can also evade immune responses by upregulating tryptophan-degrading enzymes like indole-2,3-dioxygenase (IDO1) and tryptophan-2,3-dioxygenase (TDO2) to generate the immunosuppressive metabolites kynurenine (KYN) and kynurenic acid (KA). KYN and KA bind and activate the aryl hydrocarbon receptor (AhR), which is expressed in many cell types and is well known for its broad immunosuppressive effects. Targeting the AhR with an inhibitor may therefore provide a novel immunotherapeutic approach for enhancing anti-tumoral immune responses and treating cancer.

Here we describe for the discovery and functional characterization of the first-in-class small molecule AhR inhibitor BAY 2416964. BAY 2416964 is a novel, selective and potent inhibitor of AhR that inhibits nuclear translocation of AhR and its ensuing transcriptional activity. In vitro, BAY 2416964 stimulates the pro-inflammatory activity of human T cells and KA-suppressed monocytes. In vivo, BAY 2416964 treatment inhibits tumor growth in CT26 and B16-OVA syngeneic tumor models, the latter demonstrating increases in CD8+ T cells and NK cells, and decreases in suppressive myeloid cells, in the tumor microenvironment.

Based on promising pre-clinical data, a first-in-human phase I clinical trial was initiated in 2019 in patients with advanced solid malignancies to investigate the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of BAY 2416964 (CT.gov NCT04069026). Exploratory analyses include assessment of human PK; evaluation of target engagement; assessment of immune cell markers in the tumor microenvironment and profiling of an AhR gene signature. Dose escalation of BAY 2416964 is currently ongoing.

 

Details

Date:
2nd February 2021
Time:
12:00 pm - 1:30 pm
Website:
Book now

Venue

Online

Latest news

Ludmila Milla, founder of UJJI

Ludmila Milla, founder of UJJI

Ludmila Milla is the founder of UJJI, a platform supporting its users in actively but securely working towards their goals Learn more

The First Questions to Ask Yourself when You have that Big Idea Part 1

The First Questions to Ask Yourself when You have that Big Idea Part 1

Dr Stuart Wilkinson gives advice on business ideas and how to manage them. Learn more

What is Intellectual Property (IP)?

What is Intellectual Property (IP)?

What you need to know about the ownership of your idea. Learn more

Charly Cox and Zoe Greenwood, Co-Founders of Climate Change Coaches

Charly Cox and Zoe Greenwood, Co-Founders of Climate Change Coaches

Charly Cox and Zoe Greenwood are the Co-Founders of Climate Change Coaches Learn more

Katherine French, Founder and CEO of BLUUMBIO

Katherine French, Founder and CEO of BLUUMBIO

Katherine is Founder and CEO of BLUUMBIO, a company developing new bioremediation technologies. Learn more

Veena V, Founder of Oxford Creators CIC

Veena V, Founder of Oxford Creators CIC

Veena V, is the founder of Oxford Creators CIC, supporting teens who are at risk of exclusion Learn more

Professor Elleke Boehmer, Founder of Writers Make Worlds

Professor Elleke Boehmer, Founder of Writers Make Worlds

Professor Elleke Boehmer is the founder of Writers Make Worlds, an open access educational resource hub for Black and Asian writing in Britain today Learn more

Enterprising Oxford

Tell us a bit about yourself and see information and resources relevant to your needs.

Get in touch

3 + 8 =

Copyright © 2020 Enterprising Oxford | Site by Herd